Security key
90042W100
Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (TSBX)
CUSIP: 90042W100
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 13,349,611
- Total 13F value
- $34,977,287
- Share change
- +329,030
- SEC-reported price per share
- $2.62
- Number of holders
- 40
- Value change
- +$862,899
- Number of buys
- 23
- Number of sells
- 9
- Shares outstanding
- 23,142,592
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
40
Top holders
10
TSBX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Turnstone Biologics Corp. SEC filings
Turnstone Biologics Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 90042W100
Recent filing periods:
Ownership snapshot
Top reported holders of TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2023
13F
3/4/5
Lead comparable stake: 13%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
13%
FMR LLC
11%
BANK OF AMERICA CORP /DE/
3.9%
TAKEDA PHARMACEUTICAL CO LTD
3.9%
Point72 Asset Management, L.P.
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
13%
|
$7,887,629
3,099,265 shares
|
— | 31 Dec 2023 |
| FMR LLC |
13F
3/4/5
Company · Other*
|
11%
|
$6,481,253
2,546,661 shares
|
— | 31 Dec 2023 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
3.9%
|
$2,326,278
914,058 shares
|
— | 31 Dec 2023 |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
Company
|
3.9%
|
$2,279,873
895,824 shares
|
— | 31 Dec 2023 |
| Point72 Asset Management, L.P. |
13F
Company
|
3.6%
|
$2,120,832
833,333 shares
|
— | 31 Dec 2023 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
Company
|
3.1%
|
$1,802,667
708,317 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
40
Shares
13,349,611
Rows available
40
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q3 2025 Across Filers
Q3 2025 holders
0
Q1 2024 holders
40
Holder diff
40
| Investor | Q3 2025 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q3 2025 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend